Once again the CEO is putting out a prediction of increasing enrollments with another monthly high due. We know that this latest PR is a puff piece but certainly approved by CVM and it implies that the trial is going well and gathering steam. It has a long road to hoe to meet the enrollment goal by year end but continues to sing that song..
The study is close to half way, and sites are still being added. Do u think Dr. Shaw checked out the study progress with other physicians in the study before agreeing to join the study?
" as existing centers gain more experience with Multikine,” stated CEL-SCI Chief Executive Officer Geert Kersten." Read that as more experience equals positive results. the trial is close to reaching critical mass meaning positive results will be indicated with increasing patients or poor performance and the trial stalls. CEO continues to be upbeat reflecting good performance of trial so far.
Here is your answer, Remember the trial has been ongoing for two years and has some 300 plus patients, certainly there are positive trends being seen....
Quote from the CEO
"we now also see strong interest from doctors and clinical centers in other countries too. Therefore, we are working on further expanding this global trial beyond the 21 countries in which we are already cleared to conduct the study. We expect that expanding the geography of the trial will yet further accelerate patient recruitment"
"we now also see strong interest from doctors and clinical centers in other countries too. Therefore, we are working on further expanding this global trial beyond the 21 countries in which we are already cleared to conduct the study. We expect that expanding the geography of the trial will yet further accelerate patient recruitment,”
Now that is a tell tale statement if ever I saw one. So doctors that are not in the study want to join the study. Does that speak of success?
If CVM sells an additional 25M shares and nets 70 cents per share it will dilute the current price of $1.04 to about 95 cents per share a dilution of 9 to ten cents. And CVM gets an additional $17.5 which gets them thru 2015.
It seems to me that Geert is putting himself way out on a limb. He has spoken and written about it being undervalued numerous times this month and has paid for the press with the company's funds. Next week CVM will disclose its initial patient starts for the month of Feb.. If it is not between at least 24 to 30 new starts then the recent stock rise will collapse. Can he possibly put this much pump into this trial and not achieve a good number. Really, with all the hype the CEO has released I think the start up patient count for Feb has to reach a new monthly high.
CVM has been conducting this trial for a couple of years with over 300 patients enrolled. Would additional countries be approving this trial if the trial was not going well? Some patients are hitting the three year time line and no bad news has been disclosed. TIme seems to be verifying the trials success..
CVM trial numbers beginning to accumulate and early trial results are probably beginning to trickle in. That it has gone on this long without negative news regarding first patients must be a good sign and probably will result in faster sign ups